SCHEMBL25229359

SCHEMBL25229359

CCOC(=O)c1sc2cc(Cl)ccc2c1Br

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 3/20 0.48
▸ BCKDK O14874 1/20 0.48
▸ RXFP1 Q9HBX9 1/20 0.48
▸ MAPT P10636 6/20 0.47
▸ KDM4E B2RXH2 4/20 0.47
▸ ALDH1A1 P00352 3/20 0.45
▸ TRPM8 Q7Z2W7 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ NPSR1 Q6W5P4 2/20 0.44
▸ LMNA P02545 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ ALOX15 P16050 4/20 0.44
▸ BCL2 P10415 1/20 0.44
▸ BCL2L1 Q07817 1/20 0.44
▸ BAD Q92934 1/20 0.44
▸ NPC1 O15118 1/20 0.43
▸ GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31015910 1.00 MCL1 (0.48) MCL1BCKDKRXFP1MAPTKDM4E
SCHEMBL3680399 0.86 MCL1 (0.50) MCL1BCKDKRXFP1MAPTKDM4E
SCHEMBL31015986 0.85 RXFP1 (0.51) MCL1BCKDKRXFP1MAPTKDM4E
SCHEMBL25257143 0.85 RXFP1 (0.51) MCL1BCKDKRXFP1MAPTKDM4E
SCHEMBL11681838 0.84 KDM4E (0.57) MCL1BCKDKRXFP1MAPTKDM4E
SCHEMBL25575157 0.84 MCL1 (0.48) MCL1BCKDKRXFP1MAPTKDM4E
SCHEMBL2823881 0.80 MAPT (0.49) MAPTALDH1A1MEN1HTTKMT2A
SCHEMBL31015963 0.79 ALDH1A1 (0.46) RXFP1MAPTKDM4EALDH1A1MAPK1
SCHEMBL25230246 0.79 ALDH1A1 (0.46) RXFP1MAPTKDM4EALDH1A1MAPK1
SCHEMBL6824033 0.78 MAPT (0.49) MCL1BCKDKRXFP1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466803-B2 BCKDK inhibitors and/or degraders PFIZER INC. (US) 2025-11-11 — — US disclosed
WO-2023100061-A1 3-PHENYL-1-BENZOTHIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS BRANCHED-CHAIN ALPHA KETO ACID DEHYDROGENASE KINASE INHIBITORS FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART FAILURE PFIZER INC. (US) 2023-06-08 — — WO disclosed
WO-2023100061-A1 3-PHENYL-1-BENZOTHIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS BRANCHED-CHAIN ALPHA KETO ACID DEHYDROGENASE KINASE INHIBITORS FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART FAILURE PFIZER INC. (US) 2023-06-08 — — WO disclosed
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS PFIZER INC. (US) 2023-06-01 — — US disclosed
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS PFIZER INC. (US) 2023-06-01 — — US disclosed
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS PFIZER INC. (US) 2023-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466803-B2 BCKDK inhibitors and/or degraders BCKDK, KHK, PDK4 MCL1 2996/4885BCKDK 1/4885RXFP1 3315/4885
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS BCKDK, KHK, PDK4 MCL1 2996/4885BCKDK 1/4885RXFP1 3315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback